Document Detail

Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis.
MedLine Citation:
PMID:  22160375     Owner:  NLM     Status:  Publisher    
"Disease activity free" in relapsing-remitting multiple sclerosis (RRMS) is a new concept introduced by the results of the AFFIRM study. Our objective was to analyze the clinical and radiological efficacy of natalizumab treatment in actual clinical practice and compare it with the post hoc analysis of the AFFIRM study. All patients with RRMS who began treatment with natalizumab at our two French MS centres between April 2007 and May 2008 were included and followed-up for at least 2 years. No measurable disease activity ("disease activity free") was defined as no activity on clinical measures (no relapses and no sustained disability progression) and radiological measures (no gadolinium-enhancing lesions and no new T2-hyperintense lesions on cerebral MRI). A total of 193 patients were included. Natalizumab was discontinued in 25.9% of cases before the completion of 2 years of treatment. In our cohort, we observed patients with more severe disease than in the AFFIRM study. The proportion of patients remaining free of clinical activity during 2 years of treatment was lower than in the AFFIRM study (37.8% vs. 64.3%). The proportion of patients remaining free of radiological activity during 2 years of treatment was higher than in the AFFIRM study (68.9% vs. 57.7%), while the proportion of patients remaining free of disease activity during 2 years of treatment was comparable to the AFFIRM study (33.3% vs. 36.7%). Natalizumab seems to be as effective in a real-life setting as in pivotal and post hoc studies. The confirmation of such benefits is important because of the progressive multifocal leukoencephalopathy risk.
A Melin; O Outteryck; N Collongues; H Zéphir; M C Fleury; F Blanc; A Lacour; J C Ongagna; A S Berteloot; P Vermersch; J de Sèze
Related Documents :
12590645 - A prospective study of thyroid function, morphology and autoimmunity in young patients ...
1574955 - Reversible primary hypothyroidism and elevated serum iodine level in patients with rena...
3053825 - Neoplasms of the conchal bowl: treatment with mohs micrographic surgery.
15994745 - Development and clinical impact of thyroglobulin antibodies in patients with differenti...
20863205 - Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis pat...
9030105 - Use of nasba rna amplification for detection of mycobacterium leprae in skin biopsies f...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-13
Journal Detail:
Title:  Journal of neurology     Volume:  -     ISSN:  1432-1459     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Neurology, Université Lille Nord de France, Roger Salengro Hospital, 1 Rue Emile Laine, 59037, Lille Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what i...
Next Document:  EGFL7: a unique angiogenic signaling factor in vascular development and disease.